Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 6/20 | 0.59 |
| ▸ | CTSK | P43235 | 5/20 | 0.59 |
| ▸ | CTSB | P07858 | 2/20 | 0.59 |
| ▸ | CTSL | P07711 | 1/20 | 0.59 |
| ▸ | ACE | P12821 | 1/20 | 0.57 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | AKT1 | P31749 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | PPARA | Q07869 | 5/20 | 0.50 |
| ▸ | PPARG | P37231 | 4/20 | 0.50 |
| ▸ | PPARD | Q03181 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16944141 | 0.93 | CTSS (0.58) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL27720494 | 0.90 | CTSS (0.53) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL18947456 | 0.89 | CTSS (0.51) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL17022186 | 0.89 | CTSS (0.51) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL20799203 | 0.89 | CTSS (0.62) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL1195924 | 0.88 | PPARG (0.55) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL1195926 | 0.88 | PPARG (0.55) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL12191569 | 0.88 | PPARA (0.49) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL15083188 | 0.86 | CTSS (0.60) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL16288685 | 0.86 | CTSS (0.60) | CTSSCTSKCTSBCTSLACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2161277-B1 | Asymmetric synthesis of peptides | UNIV READING (GB) | 2013-04-10 | — | — | EP | disclosed |
| US-8399612-B2 | Asymmetric synthesis of peptides | UNIVERSITY OF READING (GB) | 2013-03-19 | — | — | US | disclosed |
| US-8399612-B2 | Asymmetric synthesis of peptides | UNIVERSITY OF READING (GB) | 2013-03-19 | — | — | US | disclosed |
| US-20120190816-A9 | ASYMMETRIC SYNTHESIS OF PEPTIDES | UNIVERSITY OF READING | 2012-07-26 | — | — | US | disclosed |
| US-20120190816-A9 | ASYMMETRIC SYNTHESIS OF PEPTIDES | UNIVERSITY OF READING | 2012-07-26 | — | — | US | disclosed |
| US-20110275784-A1 | ASYMMETRIC SYNTHESIS OF PEPTIDES | UNIVERSITY OF READING | 2011-11-10 | — | — | US | disclosed |
| US-20110275784-A1 | ASYMMETRIC SYNTHESIS OF PEPTIDES | UNIVERSITY OF READING | 2011-11-10 | — | — | US | disclosed |
| US-8044173-B2 | Asymmetric synthesis of peptides | UNIVERSITY OF READING (GB) | 2011-10-25 | — | — | US | disclosed |
| US-8044173-B2 | Asymmetric synthesis of peptides | UNIVERSITY OF READING (GB) | 2011-10-25 | — | — | US | disclosed |
| EP-2161277-A2 | Asymmetric synthesis of peptides | University of Reading (GB) | 2010-03-10 | — | — | EP | disclosed |
| EP-2161277-A2 | Asymmetric synthesis of peptides | University of Reading (GB) | 2010-03-10 | — | — | EP | disclosed |
| US-20080281075-A1 | ASYMMETRIC SYNTHESIS OF PEPTIDES | UNIVERSITY OF READING (GB) | 2008-11-13 | — | — | US | disclosed |
| US-20080281075-A1 | ASYMMETRIC SYNTHESIS OF PEPTIDES | UNIVERSITY OF READING (GB) | 2008-11-13 | — | — | US | disclosed |
| EP-1937708-A1 | ASYMMETRIC SYNTHESIS OF PEPTIDES | THE UNIVERSITY OF READING (GB) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007031698-A1 | ASYMMETRIC SYNTHESIS OF PEPTIDES | UNIVERSITY OF READING (GB) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275784-A1 | ASYMMETRIC SYNTHESIS OF PEPTIDES | PTMS, NGLY1, QPCT | CTSS 1296/4885CTSK 2160/4885CTSB 2362/4885 |
| US-20080281075-A1 | ASYMMETRIC SYNTHESIS OF PEPTIDES | PTMS, NGLY1, QPCT | CTSS 1296/4885CTSK 2160/4885CTSB 2362/4885 |
| US-20120190816-A9 | ASYMMETRIC SYNTHESIS OF PEPTIDES | PTMS, NGLY1, QPCT | CTSS 1296/4885CTSK 2160/4885CTSB 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.